as substrates. One normal cell strain and one patient cell strain is analyzed with a-keto-P-methyl-n-valeric acid (2-0x0-3-methylpentanoic acid (MEVA)) as a substrate.
A biphasic degradation kinetic for each BCKA is obtained for normal control subjects. The component with higher substrate affinity is affected in MSUD: for KIC the normally hyperbolic substrate curve is changed to sigmoid shape, for KIVA and MEVA as substrates this component is not detectable at all. Considering qualitative aspects of the BCKA decarboxylation kinetics intact fibroblasts yield the same results as our recent studies with the decarboxylase moieties of partially purified kidney BCKA dehydrogenase of normal individuals and one patient with classic M S U D (27).
The decarboxylation velocities for normal and patient fibroblasts with one exception differ widely at low but not at high substrate concentrations of BCKA. T o get meaningful data on the residual substrate degradation activities with intact fibroblasts of different phenotypes of M S U D physiologically low substrate concentrations are recquired in the assay. Speculation
Kinetic studies of the decarboxylation reaction for branched chain a-ketoacids with fibroblasts of patients suffering from maple syrup urine disease could yield information about the type of biochemicalabnormality in MSUD.
Maple syrup urine disease is an autosomal recessive disorder of man that is biochemically characterized by defective oxidative decarboxylation of the branched chain a-ketoacids, a-ketoisocaproic acid, a-ketoisovaleric acid, a-keto-P-methyl-n-valeric acid, derived from the amino acids, leucine, valine, and isoleucine, respectively. This metabolic step involves three specific enzyme proteins which form a multienzyme complex resembling the well known multienzyme complexes of pyruvate and a-ketoglutarate dehydrogenase (13, (23) (24) (25) . The three enzymes calalyze the following consecutive reactions: (1) decarboxylation of the ketoacids to an active aldehyde by thiamine pyrosphosphate containing decarboxylase, (2) oxidation of the active aldehyde by lipoic acid containing transacylase and transfer of the acyl group to coenzyme A-SH, (3) reoxidation of the protein-bound cofactor lipoic acid by the flavine enzyme lipoamide oxidoreductase in the presence of NADC. The latter enzyme is a constituent of the pyruvate and a-ketoglutarate dehydrogenase complex which were shown repeatedly to be intact in M S U D . Probably more than one specific dehydrogenase is responsible for the degradation of the three BCKA (3, 13, 19) .
Phenotypic heterogeneity of M S U D has been described; an intermittent type (5), intermediate types (12, 29) , and a thiamineresponsive type (30) were distinguished from the classic type which has the most severe clinical symptoms (7, 22) . Quantitative decarboxylation studies with cultured fibroblasts using radiolabeled branched chain amino acids (BCAA) as substrates revealed activities below the 2% level of normal in the case of classic M S U D and somewhat higher values for variant types (6, 29) . Besides the thiamine responsiveness and differences in enzyme activity qualitative differences between normal and mutant BCKA dehydrogenase complexes were obtained in case of classic MSUD. The BCKA decarboxylation of broken M S U D fibroblasts was shown to be resistant to cofactor stimulation in contrast to normal cells (9, 10) . Previously an altered decarboxylation moiety of the renal enzyme complex was demonstrated for a neonate who had died from classic M S U D (27) . In most studies broken cells o r solubilized enzymes were used for the respective assay. In view of the complex structural and cofactor requirements of ketoacid dehydrogenase complexes and eventual enzyme-regulating mechanisms, as in case of pyruvate dehydrogenase (17, 24) , optimal physiologic conditions are hardly to be expected in all of those assays. Extensive loss of enzyme activity accompanies the solubilization procedures (6, 36) .
Tests with viable cells instead provide an opportunity to approximate in the test system in vivo conditions as closely as possible.
Whereas phenomena like membrane transport and intracellular pools and compartmentation of branched chain keto acids are barely understood at present, it is nevertheless generally accepted that any defect in BCKA decarboxylation, as observed in MSUD, is due to a genetically determined defect of BCKA dehydrogenase(s) (31) . Accordingly, with the current state of knowledge in mind, we considered it worthwhile to try to obtain kinetic data for BCKA decarboxylation in intact normal and M S U D fibroblasts. Any clear-cut differences between normal and patient cell lines should at least throw light on abnormal mechanisms operating in vivo and eventually yield hints as to the type of biochemical abnormality involved in different M S U D mutants.
The fibroblasts were grown from skin biopsies in different subcultures. Five cell strains (CW, I K , WW, HR, TK) were taken from individuals not affected with matabolic diseases, nine cell strains from patients with differences in severity of the clinical picture of M S U D . KQ. HG, SS. and A R are patients who are doing well with a semisynthetic or low protein diet. Four patients (KC, A G , S L , CC) were more severely affected or had died. The cell strain K G is derived after prenatal diagnosis from an aborted fetus at 21 weeks of gestation homozygous for MSUD. Clinical data of the patients KC, H G , KQ. KG. and SS have been published (6, 14, 16, 28, 35) . The BCKA decarboxylation assay with fibroblasts in monolayer was performed as described previously (37) with modifications ( I ) to to keep the assay system free of BCAA except for cellular contents, and (2) to obtain a constant pH of 6.9. Fetal calf serum (FCS (41)), which was added to the test system for nutritional requirements of the cells, was passed through a Sepahdex G-10 column equilibrated with phosphate-buffered saline (PBS (42) ) and 4 g glucose were added per liter. All assay constituents were adjusted to pH 6.9 with 20 m M N-2-hydroxyethylpiperazine propamine sulfonic acid (Hepes (42)) and N a O H . The unlabeled keto acids were dissolved in PBS buffered with HEPES, the labeled ones were adjusted to pH 6.9 before use and diluted to 0.5 m M with HEPES-buffered PBS. Specific radioactivity was 58 mCi/mmol for KIC, 37.5 mCi/mmol for KIVA, 24 mCi/mmol for MEVA, and 13.1 mCi/mmol for pyruvate. In the toluene scintillation counting system the employed counting efficiency was 82%.
The medium of the cellular monolayer grown in a microtiter plate (Cooke type, 96 wells) was replaced by a freshly prepared reaction mixture composed of buffered gel-filtered FCS and HEPES-buffered PBS (2:8; v/v) containing varying amounts of radiolabeled and unlabeled ketoacids. The 14C0, that evolved during incubation in a moist atmosphere at 37' was trapped by alkaline glass fiber platelets, covering the wells. Kctoacid decarboxylation by fibroblasts was linear over 4 hr of incubation (37) .
KIC and KIVA were used as substrates in a range between 1 x and 1.605 x M. For concentrations below 5 x M (5 nmolfassay), pure radiolabeled ketoacids were applied, for higher concentrations 5 nmol 5 % labeled acid were combined constantly with varying amounts of the corresponding unlabeled substance. Reaction velocities (picomoles of CO, per microgram of cell protein in 4 hr) were calculated from the 14C0, actually measured using the ratio of labeled and unlabeled substrate in each assay. In the case of labeled MEVA the unknown ratio of the I and d isomer (the latter seems to serve as a substrate (19, 20) Cell strains of normal individuals evolved maximally 12,000-13,000 cpm and 6,100-16,800 cpm of l4COZ above the blank for K I C and KIVA, respectively. At the highest substrate concentration employed the differences were 380-430 cpm for KIC and 350-520 cpm for KIVA. Different patient cell strains in the assay evolved maximally 1,360--5,200 cpm (KIC) and 150--1,300 cpm (KIVA) of 14C0, above the blank and at the highest substrate concentration 140-450 cpm for KIC and 50-390 cpm for KIVA.
Cell protein was estimated as described previously (37 Under the assumption that experimentally obtained substrate curves were composed of two kinetic compounds, a computerized iterative program based on the equation was applied to resolve the kinetics (43) .
R E S U L T S K I C AS SUBSTRATE
The KIC decarboxylation by fibroblasts from M S U D patients and normal control subjects follows biphasic kinetics in a Michaelis-Menten plot ( The low affinity KIC decarboxylation component is sigmoidal in shape for both normal and M S U D fibroblasts. V, , , of that component is not altered in eight patients; however, it is greatly reduced for one (AG), as shown in Figure la . In Hill plots M S U D fibroblasts differ from normal controls only in the slope of the lower sections (Fig. 3a) .
KIVA A S S U B S T R A T E
Two kinetic components are also shown for normal cellular KIVA decarboxylation (Fig. Ib) . The component with higher substrate affinity is hyperbolically shaped and has characteristics similar to the corresponding decarboxylation component with KIC as a substrate; (S),,, is on the order of M KIVA (Fig. 26) . The low affinity KIVA d e c a r b~x~l a t i o n component has twice the V, , , of KIC as a substrate and is already very active at KIVA concentrations as low as 2 x M. Similar values for V, , , are revealed for this component in normal and M S U D cell strains; however, V, , , for the cell strain A G is greatly reduced, as with KIC as a substrate (Fig. Ib) . Substrate saturation is not obtained in the experiments. The substrate curves are slightly sigmoidal in shape. Kinetics of cell strains from eight patients do not contain the high affinity component when tested with KIVA as a substrate: only a pure sigmoidal kinetic is registered in each case. Consequently, Hill plots are straight lines in contrast to those for normal controls (Fig. 3b) .
M E V A A S S U B S T R A T E
MEVA decarboxylation was measured in one normal cell strain (HR) and one cell strain from a patient (CC) with substrate concentrations from 0.25 to 12 x M (Fig. 4) . It resembles the decarboxylation of KIVA. Although normal cells show biphasic kinetic data (the component with high substrate affinity is hyperbolic) the fibroblasts of patient C C exhibit a single sigmoidshaped substrate curve with no signs of an approximate saturation at the tested substrate concentrations.
Kinetic data obtained with the three substrates are summarized in Table 1 . The experimental substrate curves for control and M S U D fibroblasts with KIC and those for control fibroblasts with KIVA could be split by a computerized analysis into two additive and saturable kinetic components with different (S)o.5 values. M S U D fibroblasts with KIVA as a substrate yielded high substrate affinity components with negligible low V,,, values compared with those obtained for the low substrate affinity component.
In order to get comparable quantitative data on ketoacid decarboxylation activity in normal and M S U D cell strains, fibroblasts from the nine patients and fibroblasts from 21 normal individuals (without metabolic diseases) were tested at the same substrate concentration (5 x lo-, M of labeled KIC and KIVA, respectively). The results are listed in Table 2 . The fibroblasts of the nine patients in our assay show residual degradation activities below 5% of the mean for normal controls. Only patient SS has 7.8% of normal KIC and 5% of normal KIVA decarboxylation activity.
DISCUSSION
Although it is possible to measure the decarboxylase reaction of the BCKA dehydrogenase complex, pure enzyme kinetics cannot be obtained with intact fibroblasts since several distinct events preceed the enzymic substrate degradation. Cellular uptake of the ketoacids and transportation into the mitochondria as well as alteration of the intracellular substrate concentration by backtransamination to the animo acid analoge interfere with determination of enzyme kinetics. Furthermore, interactions of the consecutive enzymes within the BCKA dehydrogenase complex with the decarboxylating moieties cannot be excluded. We did not obtain data for the effects of cellular and mitochondria1 transport, nor could we determine the cellular levels of endogenous BCKA. All substrate concentrations mentioned in our work refer to amounts of BCKA in the extracellular reaction mixture and not to their actual concentration at the intramitochondrial location of the decarboxylase.
Intact M S U D fibroblasts accumulate endogenous substrate during cell culturing. Since free amino acid concentrations in the culture medium (21) were as high as in plasma of M S U D patients under strict dietary control (18) , maximally about 0.25 x mol endogenous substrate/assay could be expected, a figure based on data recently published (8, 18) . This amount appears not to be relevant for the calculation of the decarboxylation kinetics.
Transamination back to the corresponding amino acid might be an important route for removal of the BCKA in MSUD.
Lancaster et al. (18) concluded from their data for the BCAA and BCKA concentrations in plasma of M S U D patients that reverse transamination in these patients was very effective when BCKA concentrations did not exceed 10-fold the normal. These in vivo findings leave open the possibility that efficient transamination and reverse transamination are produced by different and orga,lspecific transarninases (18) and they are not conclusive for the present in vitro experiments with one uniform cell type only.
Since it is generally accepted that M S U D is caused by a deficient enzymic step of BCKA oxidation and no data exist to suggest a membrane or transportation defect in that disease, differences Concerning the biphasic characteristics of the kinetics for K I V A a n d M E V A decarboxylation, identical results were obtained in a previous study (27) with partially purified renal B C K A dehydrogenase complex from normal control subjects a n d a child with classic M S U D who had died. T h e decarboxylase moiety of the B C K A dehydrogenase complex was investigated by utilizing the reduction of 2,6-dichloroindophenol in the presence of thiamine pyrophosphate a s a cofactor in a cell and membrane free assay system. With 2,6-dichloroindophenol a s a n acceptor for active aldehyde, the transacylase reaction normally following the B C K A decarboxylation was eliminated. In that real enzyme assay decar- boxylase reaction for normal individuals followed biphasic kinetics with KIVA and MEVA as substrates and the high substrate affinity component was absent in classic M S U D . Because of very low activity in this assay system no sufficient data for KIC decarboxylation could then be obtained. Regrettably, fibroblasts of that special M S U D case were not at our disposal for direct comparison. Our experiments d o not elucidate whether both BCKA decarboxylation components of control fibroblasts represent two different specific decarboxylase systems. The very low substrate affinity of one decarboxylation component could also be caused by a decarboxylating enzyme with different ketoacid specificity that may exhibit some activity with the branched chain compounds. Unspecific reaction of pyruvate decarboxylase could be excluded from the uniform hyperbolic kinetics obtained with [I-14C]pyruvate as a substrate for normal and M S U D cell strains, among which was A G . Otherwise at least some variation in the kinetics would have been suspected for A G as in the case of defective pyruvate decarboxylase (2) under the same assay conditions (34) .
Biphasic substrate saturation curves can also indicate multiple forms of an enzyme under assay conditions as it was assumed for the phenylalanine hydroxylase (15) or several interacting substrate binding sites on an enzyme molecule (1 1, 32). Biphasic Hill plots are described for yeast pyruvate dehydrogenase (33) . The composition of mammalian pyruvate decarboxylase moieties out of two pairs of two different polypeptide chains as well as regulation of enzyme activity by different metabolities are established (17) . In analogy, interacting substrate binding sites were proposed as a possible basis also for the biphasic BCKA decarboxylase kinetics obtained in the 2,6-dichloroindophenol test (19) .
The fact that decarboxylation was reduced for all three BCKA in the case of M S U D analyzed up to now may indicate the presence of a special subunit common to the dehydrogenase complex for each BCKA (4). The present results support the thesis that a mutation in the gene controlling the synthesis of a common subunit of the enzyme complex may lead to M S U D . Within these bounds the special position of patient A G is obvious. U p to now there have been no indications for a mutation in a specific subunit leading to an altered decarboxylation of one BCKA only. Eventually those defects pass clinically unrecognized (19) .
Within the group of nine M S U D cell strains we obtained strikingly similar qualitative alterations of the kinetics for BCKA decarboxylation. Only small differences in the residual BCKA degradation activity were measured at 5 x M substrate concentration, which is slightly above the normal serum concentration of these substances (18) . Those differences correlate to some extent with the phenotypic expression of the disease. From our results, however, we conclude that the residual decarboxylation activity of M S U D fibroblasts observed with only one substrate concentration is not sufficient to explain the marked differences in clinical course of the patients and cannot be the basis for prognostic and therapeutic considerations as proposed (6) . The kinetic patterns indicate that these estimations are inappropriate in M S U D because the residual decarboxylation activity of the M S U D fibroblasts will depend on the selected substrate concentration and will approach normal degradation levels with increasing substrate concentrations with KIC more than with KIVA. In the range of saturating substrate concentrations the differences between normal and M S U D cell strains except for A G are within the interindividual variability of decarboxylation level for normal control subjects which is 25% in our assay. We obtained much lower residual degradation activities for variant forms of M S U D than other authors (6, 29) under similar conditions, because of the low substrate concentration (5 x M ) used. The data given in Table 1 Extract Pyritinol-HCI was tested for its impact on the cognitive functions of children with learning disabilities. This study is a contribution to scientific discussion on the complicated methodologic problems in evaluating the clinical efficacy of psychopharmacologic agents.
Sixty-seven pupils of slow learner classes between the ages of 11 and 16 years were treated for 6 months with 300 mg pyritinol-HC1/24 hr or placebo under strict double-blind conditions. Drug intake was stimulated and controlled by means of intense psychosocial interaction with the mothers of the subjects.
The dependence variables used to test medication effects were 22 parameters of cognitive performance measured in psychologic tests for perceptual and intellectual functions which were administered immediately before and after the medication phase.
First the gainscores before and after treatment with pyritinol or placebo within the 22 cognitive parameters were statistically compared. In addition, an analysis of covariance on the corrected results of the second test (treating the results of first testing as covariates) and a two group discriminant analysis for overall differences were performed, None of the 22 parameters showed statistically significant treatment effects with respect to average performance ( t (pvritino1 -placebo) = 1.96 to 1.31), neither could the two groups be separated by discriminant analysis (Hotelling's T2 = 35.4, df -22 and 43, P = 0.465).
With respect to variability of gainscores, however, in four parameters there was a significantly higher variance in the pyritinol group ( F = 1.85-2.33, P < 0.05, < 0.02, respectively). This fact may signify that pyritinol-HCI had different effects on different subjects. By means of prognostic stratification we therefore attempted to define objective criteria for a selection of subjects with probable positive treatment effects. None of the 15 tested criteria, such as body weight, age, perceptual handicaps, or reduced short term memory, IQ range, proved, however, to be critical for a prognosis of pyritinol effects within the present test population.
Speculation
Although there is no evidence for a general improvement of cognitive functions within the whole test population through treatment with pyritinol-HCI, the results presented suggest slight medication effects in a positive a s well as a negative direction for not as yet specifiable subpopulations. The definition of objective indications for the drug seems to be a major problem in testing psychopharmacologic agents.
In consideration of the increasing number of psychoactive drugs and the increasing tendency to administer them to children with behavioral and/or cognitive disorders, one could expect an increasing number of publications concerning behavioral and cognitive changes in children under the influence of psychopharmacologic agents. Nevertheless, an old complaint (6) on the lack of actual research in this field still holds true. In the last decade publications on this subject were extremely rare and some of the existing studies do not fulfill elementary methodologic criteria, as formulated by Taber (30) , for clinical drug trials. At a first glance, these facts are surprising, especially with respect to the topic of drug influences on cognitive functions. Psychology has developed a great variety of cognitive tests which provide objective criteria for measuring drug influences. Several authors (7, 16, 25, 26) , however, stress the considerable difficulties, such as patient-drug interactions, inter-
